Bayer Places Consumer Cost Of Living Pressures 'Very High' On Agenda
Executive Summary
Despite spiraling inflation, branded OTC product demand remains high, according to Bayer Consumer Health, which posted Q2 sales up by 16.0%. But with consumer incomes increasingly squeezed, the company is working on ways to defend its market share against cheaper private-label alternatives.
You may also be interested in...
Astepro Launch And Strong Cold Season Boost Bayer In Q3
The US OTC launch of reclassified nasal spray Astepro Allergy, in combination with “continuously elevated cold incidence rates,” helped to drive up Bayer's Consumer Health sales at a double-digit rate in Q3.
Euro Q3 Consumer Health Earnings Preview: Helm Changes, Investor Questions, Results Debut
Major Europe-based consumer health players Reckitt, Bayer, Sanofi and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2022 results over the coming weeks.
Bayer Suggests Self-Care Industry Follow Five Principles As 'Blueprint' For Product Development
Bayer proposes five science-based principles to guide industry’s self-care research and development to reframe self-care and earn consumer trust.